Outpatient Treatment of Severe and Enduring Anorexia Nervosa

• Sponsor: Helsinki University Central Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT05708404
• Collaborator: (none)
• Enrollment: 20
• Location: 1
• Actual Duration (Months): 61
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

Approximately 20-30 % of individuals with the eating disorder anorexia nervosa develop an enduring form of the illness. In this study a new treatment for patients with severe and enduring anorexia nervosa was described. The treatment is flexible and aims at enhancing quality of life. The participants consisted of all referrals resulting in an assessment or treatment period at the unit between May 2017 and May 2022. The study was a registry study. Information regarding patient characteristics, treatment goals, and the course of treatment was gathered from medical records.

Condition or Disease	Intervention/Treatment	Phase
Anorexia	Behavioral: Outpatient treatment of severe and enduring anorexia nervosa

Study Design

• Study Type: Observational
• Actual Enrollment: 20 participants
• Observational Model: Cohort
• Time Perspective: Retrospective
• Official Title: A Novel Outpatient Treatment for Patients With Severe and Enduring Anorexia Nervosa: Patient Characteristics, Treatment Goals, and Course of Treatment.
• Actual Study Start Date: May 1, 2017
• Actual Primary Completion Date: May 31, 2022
• Actual Study Completion Date: May 31, 2022

Outcome Measures

Primary Outcome Measures

1. How the treatment goals were met [At the end of treatment, an average of 15.4 months]

   Whether or not the patients' individual treatment goals, defined at the beginning of treatment, had been met, partly met, or not met at the end of treatment.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female

Inclusion criteria:

• Age ≥ 18 years

• A referral resulting in an assessment or treatment period at the unit for patients with severe and enduring anorexia nervosa at the HUS Helsinki University Hospital between May 2017 and May 2022.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	HUS Syömishäiriöyksikkö	Helsinki	Pl 282	Finland	00029 HUS

Sponsors and Collaborators

• Helsinki University Central Hospital

Investigators

• Principal Investigator: Jaana Suokas, Ph.D., HUS Helsinki Central Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Monica Algars, Ph.D., Helsinki University Central Hospital
• ClinicalTrials.gov Identifier: NCT05708404
• Other Study ID Numbers: PISARAAVO
• First Posted: Feb 1, 2023
• Last Update Posted: Feb 1, 2023
• Last Verified: Jan 1, 2023

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Monica Algars, Ph.D., Helsinki University Central Hospital: Anorexia nervosa; Severe and enduring anorexia nervosa; Treatment
• Additional relevant MeSH terms: Anorexia; Anorexia Nervosa

Study Results

No Results Posted as of Feb 1, 2023